Trials / Completed
CompletedNCT00165646
A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease
A Double-Blind, Placebo-Controlled, Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 288 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal reflux disease in a multicenter, randomized, double-blind, comparative study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E3810 | E3810 5mg: once daily orally for 4 weeks |
| DRUG | E3810 | E3810 10mg: once daily orally for 4 weeks |
| DRUG | Placebo | Placebo: once daily orally for 4 weeks |
Timeline
- Start date
- 2004-09-01
- Primary completion
- 2005-10-01
- Completion
- 2005-10-01
- First posted
- 2005-09-14
- Last updated
- 2011-07-18
- Results posted
- 2011-06-17
Locations
35 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00165646. Inclusion in this directory is not an endorsement.